30
300676.SHE BGI Genomics Co Ltd
- Market cap
- CNY 15.6B
- P/E
- -
- P/B
- 1.87x
- ROE
- 0.8%
- Dividend yield
- 0.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300676.SHE undervalued?
Graham numberThe Graham number of BGI Genomics Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BGI Genomics Co Ltd fundamental analysis
No fundamental analysis for BGI Genomics Co Ltd yet.
BGI Genomics Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and me…
Full company profileBGI Genomics Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BGI Genomics Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.71B | 2.10B | 2.54B | 2.80B | 8.40B | 6.77B | 7.05B | 4.35B | 3.87B | 3.71B | 3.59B |
| Gross Profit | 1.02B | 1.19B | 1.40B | 1.50B | 5.01B | 3.92B | 3.53B | 2.15B | 1.50B | 1.39B | 1.46B |
| Operating Income | 381M | 504M | 478M | 330M | 2.50B | 1.82B | 1.09B | 151M | -875M | -170M | 187M |
| EBITDA | 381M | 525M | 536M | 499M | 2.95B | 1.96B | 1.26B | 483M | -321M | -48.3M | 99.1M |
| Net Income | 333M | 398M | 387M | 276M | 2.09B | 1.46B | 803M | 92.9M | -903M | -617M | 67.0M |
| EPS | 0.92 | 1.05 | 0.97 | 0.69 | 5.24 | 3.55 | 1.96 | 0.23 | -2.19 | -1.47 | 0.16 |
| Balance Sheet | |||||||||||
| Total Assets | 4.23B | 5.11B | 5.13B | 5.97B | 11.3B | 14.3B | 14.4B | 13.6B | 12.5B | 11.7B | 11.1B |
| Total Liabilities | 778M | 854M | 1.00B | 1.52B | 5.32B | 4.81B | 4.16B | 3.61B | 3.27B | 3.14B | 2.75B |
| Shareholders' Equity | 3.36B | 4.15B | 4.05B | 4.37B | 5.91B | 9.32B | 10.1B | 9.86B | 9.13B | 8.49B | 8.24B |
| Cash & Short-term Investments | 749M | 2.70B | 1.53B | 1.22B | 5.43B | 8.64B | 6.39B | 5.49B | 4.31B | 3.29B | 2.65B |
| Total Debt | 3.00M | 8.00M | 31.1M | 301M | 1.37B | 721M | 137M | 283M | 414M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 234M | 244M | 14.7M | 224M | 3.60B | 2.48B | 131M | 409M | 95.7M | -63.2M | - |
| Capital Expenditure | 246M | 291M | 678M | 626M | 301M | 384M | 1.27B | 1.24B | 529M | 506M | 426M |
| Free Cash Flow | -11.9M | -64.8M | -663M | -402M | 3.30B | 2.09B | -1.13B | -828M | -434M | -569M | -568M |
| Ratios | |||||||||||
| ROE | 9.9% | 9.6% | 9.5% | 6.3% | 35.4% | 15.7% | 8.0% | 0.9% | -9.9% | -7.3% | 0.8% |
| ROA | 7.9% | 7.8% | 7.5% | 4.6% | 18.4% | 10.3% | 5.6% | 0.7% | -7.2% | -5.2% | 0.6% |
| Net Profit Margin | 19.4% | 19.0% | 15.2% | 9.9% | 24.9% | 21.6% | 11.4% | 2.1% | -23.3% | -16.6% | 1.9% |
| Debt to Equity | 0.00x | 0.00x | 0.01x | 0.07x | 0.23x | 0.08x | 0.01x | 0.03x | 0.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BGI Genomics Co Ltd dividends
- Dividend yield
- 0.11%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 4, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 17.3M | 0.04 | - |
| 2024 | CNY 50.4M | 0.12 | - |
| 2023 | CNY 417M | 1.01 | 448.6% |
| 2022 | CNY 143M | 0.35 | 17.9% |
| 2021 | CNY 145M | 0.35 | 9.9% |
| 2020 | CNY 40.0M | 0.10 | 1.9% |
| 2019 | CNY 40.0M | 0.10 | 14.5% |
| 2018 | CNY 200M | 0.50 | 51.8% |
| 2017 | CNY 109M | 0.29 | 27.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BGI Genomics Co Ltd
- Insiders 39.21%
- Institutions 5.89%
- Public & others 54.90%
- Shares outstanding 418M
- Free float 236M
BGI Genomics Co Ltd company profile
- Company name
- BGI Genomics Co Ltd
- Ticker
- 300676.SHE
- ISIN
- CNE100003449
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,580
- Fiscal year end
- December
- Address
- BGI Center, Shenzhen, China, 518081
- Phone
- 86 400 706 6615
- Website
- bgi.com
About BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and metagenomics and 16S/18S/ITS sequencing. It also provides RNA sequencing, long non-coding RNA sequencing, small RNA sequencing, iso-seq / pacbio transcriptome sequencing; single cell sequencing and high throughput single cell RNA-Seq; spatial transcriptome-stereo-seq; immune repertoire and pre-made library sequencing; and bioinformatics solutions. In addition, the company offers mass spectrometry, including proteomics, metabolomics, and multi-omics. Further, it provides clinical solutions for reproductive health, oncology, infectious disease, and chronic disease. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. The company was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd. operates as a subsidiary of BGI Group.
BGI Genomics Co Ltd management
8- Mr. Yujue WangCFO, Deputy GM & Non Independent Director · born 1978
- Ms. Qian XuDirector of Legal Affairs, General Counsel, Deputy GM & Secretary · born 1984
- Mr. Hao LiDeputy GM and Head of Marketing Center & i99 Division · born 1982
- Mr. Shida ZhuDeputy GM & Non Independent Director · born 1987
- Ms. Yun YangVP & Head of Product Center · born 1979
- Mr. Yong HouGeneral Manager · born 1989
- Yun Yang Ph.D.Deputy General Manager
- Mr. Weijun ChenDeputy General Manager · born 1972